PT-141 (Bremelanotide)

PT-141, generic name bremelanotide, is a synthetic analog of the alpha-melanocyte-stimulating hormone that works on melanocortin receptors (MC3R and MC4R) in the central nervous system to influence sexual desire and arousal.¹ FDA-approved in 2019 for premenopausal women with hypoactive sexual desire disorder under the brand name Vyleesi, it is used off-label in men with similar desire-pattern issues.²

How it works

Most ED medications — sildenafil, tadalafil, the rest of the PDE5 inhibitors — act on penile blood flow. They make the mechanical erection happen but do nothing for desire. PT-141 works upstream: it activates melanocortin receptors in the hypothalamus that modulate sexual motivation directly.¹³ For men whose limiting factor is desire rather than vascular response, that distinction matters.

Who it is for

PT-141 is for men with a desire-pattern complaint: difficulty initiating or feeling motivation for sexual activity, with adequate vascular response when desire is present. Before recommending it, a good provider will rule out the more common causes of reduced desire first — low testosterone, antidepressant side effects, sleep deprivation, relationship factors.⁴ PT-141 is not a substitute for PDE5 inhibitors when the issue is mechanical, nor a wholesale replacement for treating underlying causes.

Dosing and administration

Administered as a subcutaneous injection roughly 45 minutes before anticipated sexual activity. Typical starting dose is 1.25 mg, titrated up to 1.75 mg if tolerated. Effect is felt within 1–3 hours and lasts up to 24 hours.² Maximum recommended frequency is 8 doses per month.

Side effects + considerations

• Most common: nausea (40%+ of users at full dose), flushing, headache.²
• Transient blood-pressure changes — typically a 6–8 mmHg rise that resolves within hours. Patients with uncontrolled hypertension or cardiovascular disease should be screened first.²
• Focal hyperpigmentation has been reported with repeated use — usually reversible after discontinuation.
• Not recommended in combination with naltrexone or chronic opioid use.